Altre lingue NeuroSense Therapeutics Ltd.

Azioni

NRSN

IL0011809592

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 02/07/2024			Variaz. 5gg	Var. 1 gen.
1,24 ^USD	+14,81%		+46,57%	+57,96%

01/07	NeuroSense Therapeutics Ltd. riporta i risultati statisticamente significativi dello studio Paradigm a 12 mesi che valuta PrimeC nelle persone affette da Sclerosi Laterale Amiotrofica	CI
24/06	NeuroSense Therapeutics Ltd. riporta i risultati degli utili per il primo trimestre conclusosi il 31 marzo 2024	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

NeuroSense Demonstrates Statistically Significant Efficacy and Survival Benefits in People Living with ALS, The Promising Results from the 12-Month PARADIGM Study Highlight PrimeC's Potential as a Disease Modifying Drug	02/07
NeuroSense Demonstrates Statistically Significant Efficacy and Survival Benefits in People Living with ALS: The Promising Results from the 12-Month PARADIGM Study Highlight PrimeC's Potential as a Disease Modifying Drug	01/07
NeuroSense Therapeutics Ltd. Reports Statistically Significant Results from the 12-Month Paradigm Study Evaluating PrimeC in People Living with Amyotrophic Lateral Sclerosis	01/07
Global markets live: Novo Nordisk, Apple, UPS, Eli Lilly, Qualcomm...	24/06
NeuroSense Therapeutics Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	24/06
NeuroSense Management Provides Corporate Update and First Quarter 2024 Financial Results	24/06
La zone euro veut éviter son moment Liz Truss	24/06
En Direct des Marchés : Thales, Orange, Safran, Casino, Prosus, Apple, Julius Bär, Hugo Boss...	24/06
Bolsa de Madrid: La eurozona quiere evitar su momento Liz Truss	24/06
NeuroSense Therapeutics Receives Delisting Notice From Nasdaq	21/06
NeuroSense Receives Delisting Notice from Nasdaq and Intends to Appeal	21/06
NeuroSense Therapeutics : INDEX TO CONSOLIDATED FINANCIAL STATEMENTS Form 6 K	17/06
NeuroSense Therapeutics : NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JUNE 27, 2024 - Form 6-K	28/05
NeuroSense Therapeutics : NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JUNE 27, 2024 - Form 6-K	23/05
NeuroSense Vice President of R&D Shiran Zimri, Ph.D. to Participate in the 3rd Annual ALS Drug Development Summit	20/05
NeuroSense Partners with PhaseV for ALS Treatment Trial -- Shares Up	14/05
NeuroSense Partners with PhaseV to Optimize Upcoming ALS Phase 3 Trial Using Advanced Causal Machine Learning	14/05
NeuroSense Therapeutics : Partners with PhaseV to Optimize Upcoming ALS Phase 3 Trial Using Advanced Causal Machine Learning - Form 6-K	14/05
NeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing of Disease Progression in High-Risk ALS Patients	07/05
NeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing of Disease Progression in High-Risk ALS Patients	07/05

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue NeuroSense Therapeutics Ltd.

Azioni

NRSN

IL0011809592

Altre lingue

Filtri